Stockreport

CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies

CervoMed Inc.  (CRVO) 
PDF FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Dru [Read more]